Genenta Science (GNTA) Competitors $3.75 -0.13 (-3.35%) As of 01:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNTA vs. TSHA, ESPR, TKNO, ATAI, ATYR, CADL, PROK, CMPS, CMPX, and PRMEShould you be buying Genenta Science stock or one of its competitors? The main competitors of Genenta Science include Taysha Gene Therapies (TSHA), Esperion Therapeutics (ESPR), Alpha Teknova (TKNO), Atai Life Sciences (ATAI), Atyr PHARMA (ATYR), Candel Therapeutics (CADL), ProKidney (PROK), COMPASS Pathways (CMPS), Compass Therapeutics (CMPX), and Prime Medicine (PRME). These companies are all part of the "pharmaceutical products" industry. Genenta Science vs. Taysha Gene Therapies Esperion Therapeutics Alpha Teknova Atai Life Sciences Atyr PHARMA Candel Therapeutics ProKidney COMPASS Pathways Compass Therapeutics Prime Medicine Genenta Science (NASDAQ:GNTA) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, community ranking, profitability, valuation and analyst recommendations. Do analysts recommend GNTA or TSHA? Genenta Science presently has a consensus price target of $25.00, indicating a potential upside of 566.67%. Taysha Gene Therapies has a consensus price target of $6.63, indicating a potential upside of 440.82%. Given Genenta Science's higher possible upside, research analysts clearly believe Genenta Science is more favorable than Taysha Gene Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Taysha Gene Therapies 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, GNTA or TSHA? Genenta Science has higher earnings, but lower revenue than Taysha Gene Therapies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenenta ScienceN/AN/A-$12.60MN/AN/ATaysha Gene Therapies$8.33M30.14-$111.57M-$0.36-3.40 Does the MarketBeat Community favor GNTA or TSHA? Taysha Gene Therapies received 100 more outperform votes than Genenta Science when rated by MarketBeat users. However, 87.50% of users gave Genenta Science an outperform vote while only 77.54% of users gave Taysha Gene Therapies an outperform vote. CompanyUnderperformOutperformGenenta ScienceOutperform Votes787.50% Underperform Votes112.50%Taysha Gene TherapiesOutperform Votes10777.54% Underperform Votes3122.46% Does the media prefer GNTA or TSHA? In the previous week, Genenta Science and Genenta Science both had 1 articles in the media. Genenta Science's average media sentiment score of 1.79 beat Taysha Gene Therapies' score of 0.00 indicating that Genenta Science is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genenta Science 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Taysha Gene Therapies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in GNTA or TSHA? 15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by company insiders. Comparatively, 2.7% of Taysha Gene Therapies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is GNTA or TSHA more profitable? Genenta Science has a net margin of 0.00% compared to Taysha Gene Therapies' net margin of -229.67%. Genenta Science's return on equity of 0.00% beat Taysha Gene Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Genenta ScienceN/A N/A N/A Taysha Gene Therapies -229.67%-106.36%-49.16% Which has more volatility & risk, GNTA or TSHA? Genenta Science has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. SummaryGenenta Science beats Taysha Gene Therapies on 8 of the 13 factors compared between the two stocks. Remove Ads Get Genenta Science News Delivered to You Automatically Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNTA vs. The Competition Export to ExcelMetricGenenta ScienceBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$68.59M$2.86B$5.33B$7.16BDividend YieldN/A1.53%4.87%4.06%P/E RatioN/A29.4622.9417.50Price / SalesN/A418.53357.9385.03Price / CashN/A168.6838.1634.64Price / Book3.103.476.263.82Net Income-$12.60M-$72.06M$3.21B$247.19M7 Day Performance-5.66%-12.78%-7.86%-7.19%1 Month Performance-1.60%-20.03%-2.83%-9.97%1 Year Performance13.98%-33.86%3.74%-7.26% Genenta Science Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNTAGenenta Science2.8323 of 5 stars$3.75-3.4%$25.00+566.7%+14.0%$68.59MN/A0.007Positive NewsGap DownTSHATaysha Gene Therapies1.8869 of 5 stars$1.39-28.0%$6.63+376.6%-53.7%$284.95M$8.33M2.21180News CoverageGap DownHigh Trading VolumeESPREsperion Therapeutics3.6291 of 5 stars$1.44-4.0%$6.75+368.8%-58.7%$284.90M$332.31M-2.25200TKNOAlpha Teknova1.1304 of 5 stars$5.19-0.4%$8.50+63.8%+94.8%$277.34M$37.75M-7.01240Positive NewsGap DownHigh Trading VolumeATAIAtai Life Sciences3.4389 of 5 stars$1.36-7.5%$9.00+561.8%-45.0%$269.70M$308,000.00-1.6880ATYRAtyr PHARMA2.5451 of 5 stars$3.02-3.5%$18.60+515.9%N/A$268.35M$235,000.00-3.2153Positive NewsGap DownHigh Trading VolumeCADLCandel Therapeutics2.1685 of 5 stars$5.65-5.0%$21.00+271.7%+212.5%$266.88M$120,000.00-3.2760Gap DownPROKProKidney1.4287 of 5 stars$0.88-3.7%$5.00+470.6%-52.3%$266.36M$76,000.00-1.593Gap DownCMPSCOMPASS Pathways3.2306 of 5 stars$2.86-2.7%$21.83+663.4%-70.8%$265.05MN/A-1.30120CMPXCompass Therapeutics2.9979 of 5 stars$1.90-4.5%$11.38+498.7%-13.2%$262.74M$850,000.00-5.1320Analyst ForecastOptions VolumeAnalyst RevisionNews CoverageHigh Trading VolumePRMEPrime Medicine2.2777 of 5 stars$1.99flat$13.38+572.1%-72.2%$261.01M$2.98M-0.97234Gap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Taysha Gene Therapies Competitors Esperion Therapeutics Competitors Alpha Teknova Competitors Atai Life Sciences Competitors Atyr PHARMA Competitors Candel Therapeutics Competitors ProKidney Competitors COMPASS Pathways Competitors Compass Therapeutics Competitors Prime Medicine Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNTA) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredRUTHLESS Musk Move >> coming June 1?Elon Musk has made headlines with everything from mass layoffs to political drama — but his next move could sh...Paradigm Press | SponsoredNearly $3 Trillion Gone…Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow you could profit from Elon’s latest AI breakthroughEvery single one of Elon's projects minted an entire new class of millionaires. And xAI could be next in li...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredTrump’s betrayal exposed Fair warning: this will not make for easy viewing. Especially if you voted for Trump, put your faith in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genenta Science S.p.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genenta Science With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GNTA Stock Free GNTA Stock Alerts